3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
1
Interventions
Cyclophosphamide
222
pembrolizumab
201
Carboplatin
173
Cisplatin
168
Gemcitabine
167
Paclitaxel
155
Docetaxel
140
Bevacizumab
138
Rituximab
137
Radiotherapy
137
Nivolumab
126
Dexamethasone
126
Capecitabine
103
fludarabine
102
Pemetrexed
92
fludarabine phosphate
91
Fluorouracil
91
Doxorubicin
85
Oxaliplatin
79
Etoposide
77
Cytarabine
77
Bortezomib
76
Erlotinib Hydrochloride
74
Leucovorin
72
Filgrastim
68
Lenalidomide
67
Calcium Dobesilate
66
Irinotecan
65
atezolizumab
63
Radiation
61
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Has results
×
balixafortide
×
Clear all
NCT03786094
2023-11-01
FORTRESS
Spexis AG
Phase 3
Terminated
432 enrolled
13 charts